Product Description
Nabilone is used to treat nausea and vomiting caused by cancer chemotherapy in people who have already taken other medications to treat this type of nausea and vomiting without good results. Nabilone is in a class of medications called cannabinoids. (Sourced from: https://medlineplus.gov/druginfo/meds/a607048.html)
Mechanisms of Action: CB1 Agonist, CB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Canada | Germany | Greece | Ireland | Israel | United Kingdom | United States
Approved Indications: None
Company: OA Dr. Philipp Becker c/o Abteilung für Wirbelsäulenchirurgie, Orthopädisches Spital Speising GmbH
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Marijuana Abuse
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05494437 |
CAN-002 | P2 |
Completed |
Marijuana Abuse |
2023-08-21 |
12% |
2023-12-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/19/2025 |
News Article |
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at The College on Problems of Drug Dependence Annual Meeting |
|
11/18/2024 |
News Article |
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at AAAP Annual Meeting |
|
09/09/2024 |
News Article |
Medical Marijuana Market to Grow by USD 39.8 Billion (2024-2028), Driven by Product Launches, How AI is Shaping the Market - Technavio Report |
|
02/23/2024 |
News Article |
FDA Moves Ahead With MMJ Cannabis Drug Application |